JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Deciphering the prognostic signature of nonsmall cell lung cancer using cisplatin resistance and circulating tumor cell-related gene analysis

  • 0Department of Oncology, Zibo Hospital of Integrated Chinese and Western Medicine, Zibo, Shandong Province China.
3 Biotech +

|

July 21, 2025

|

July 21, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed an eight-gene model to predict nonsmall cell lung cancer (NSCLC) prognosis and cisplatin resistance. Targeting FAM83A shows potential for reversing resistance and improving treatment efficacy.

Area Of Science

  • Oncology
  • Genomics
  • Molecular Biology

Background

  • Nonsmall cell lung cancer (NSCLC) poses a significant health challenge, with cisplatin resistance and circulating tumor cell (CTC)-related genes impacting patient outcomes.
  • Developing accurate prognostic models is crucial for personalized treatment strategies in NSCLC.

Purpose Of The Study

  • To develop a prognostic prediction model for NSCLC utilizing cisplatin resistance and CTC-related genes.
  • To explore the molecular mechanisms of key genes involved in NSCLC progression and treatment resistance.
  • To investigate the potential of targeting FAM83A to overcome cisplatin resistance.

Main Methods

  • Utilized data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
  • Developed a prognostic signature using Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis.
  • Validated key gene expression using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in NSCLC cell lines (A549 and A549/DDP).

Main Results

  • An eight-gene prognostic signature was developed, with high-risk patients exhibiting significantly lower survival rates.
  • The risk score served as an independent predictor of NSCLC prognosis and demonstrated significant differences in immune infiltration.
  • The model effectively predicted responses to immunotherapy and chemotherapy, and FAM83A inhibition reversed cisplatin resistance.
  • FAM83A overexpression promoted proliferation and invasion while inhibiting apoptosis in NSCLC cells.

Conclusions

  • The developed eight-gene model accurately predicts NSCLC prognosis and can guide personalized treatment decisions.
  • Targeted inhibition of FAM83A offers a novel strategy to reverse cisplatin resistance and potentially enhance combined chemotherapy and immunotherapy efficacy.

Keywords: